Literature DB >> 19602548

Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation.

Gregory L Beatty1, Jasmine S Smith, Ran Reshef, Kunal P Patel, Theresa A Colligon, Barbara A Vance, Noelle V Frey, F Brad Johnson, David L Porter, Robert H Vonderheide.   

Abstract

PURPOSE: The therapeutic effect of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with myeloid malignancies has been attributed in part to a graft-versus-leukemia effect that is dependent on donor T lymphocytes. CD8(+) T-cell responses to MHC class I-restricted tumor epitopes, not just allogeneic antigens, may help mediate antileukemia effects after HSCT, but the specificity and function of such cells are not completely understood. EXPERIMENTAL
DESIGN: We examined the diversity, phenotype, and functional potential of leukemia-associated antigen-specific CD8(+) T cells in patients with myeloid leukemia following allogeneic HSCT. Screening for antigen-specific T cells was accomplished with a peptide/MHC tetramer library.
RESULTS: Patients with acute myelogenous leukemia or chronic myelogenous leukemia in remission following HSCT exhibited significant numbers of peripheral blood CD8(+) T cells that recognized varying combinations of epitopes derived from leukemia-associated antigens. However, these cells failed to proliferate, release cytokines, or degranulate in response to antigen-specific stimuli. As early as 2 months after HSCT, CD8(+) T cells from patients were predominantly CD28(-) CD57(+) and had relatively short telomeres, consistent with cellular senescence.
CONCLUSIONS: Circulating leukemia-specific CD8(+) T cells are prominent in myeloid leukemia patients after HSCT, but such cells are largely functionally unresponsive, most likely due to replicative senescence. These findings carry important implications for the understanding of the graft-versus-leukemia effect and for the rational design of immunotherapeutic strategies for patients with myeloid leukemias.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602548      PMCID: PMC2722844          DOI: 10.1158/1078-0432.CCR-08-3332

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

3.  Accelerated replicative senescence of the peripheral immune system induced by HIV infection.

Authors:  L J Bestilny; M J Gill; C H Mody; K T Riabowol
Journal:  AIDS       Date:  2000-05-05       Impact factor: 4.177

4.  Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.

Authors:  Lydie Trautmann; Loury Janbazian; Nicolas Chomont; Elias A Said; Sylvain Gimmig; Benoit Bessette; Mohamed-Rachid Boulassel; Eric Delwart; Homero Sepulveda; Robert S Balderas; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sekaly
Journal:  Nat Med       Date:  2006-08-20       Impact factor: 53.440

5.  Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.

Authors:  Jochen Greiner; Michael Schmitt; Li Li; Krzysztof Giannopoulos; Katrin Bosch; Anita Schmitt; Konstanze Dohner; Richard F Schlenk; Jonathan R Pollack; Hartmut Dohner; Lars Bullinger
Journal:  Blood       Date:  2006-08-24       Impact factor: 22.113

6.  Four functionally distinct populations of human effector-memory CD8+ T lymphocytes.

Authors:  Pedro Romero; Alfred Zippelius; Isabel Kurth; Mikaël J Pittet; Cédric Touvrey; Emanuela M Iancu; Patricia Corthesy; Estelle Devevre; Daniel E Speiser; Nathalie Rufer
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

7.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.

Authors:  J J Molldrem; P P Lee; C Wang; K Felio; H M Kantarjian; R E Champlin; M M Davis
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

8.  Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.

Authors:  C Heining; A Spyridonidis; E Bernhardt; J Schulte-Mönting; D Behringer; C Grüllich; A Jakob; H Bertz; J Finke
Journal:  Bone Marrow Transplant       Date:  2007-03-26       Impact factor: 5.483

9.  Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias.

Authors:  H J Lawrence; S Rozenfeld; C Cruz; K Matsukuma; A Kwong; L Kömüves; A M Buchberg; C Largman
Journal:  Leukemia       Date:  1999-12       Impact factor: 11.528

Review 10.  Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.

Authors:  A W Loren; D L Porter
Journal:  Bone Marrow Transplant       Date:  2007-11-19       Impact factor: 5.483

View more
  21 in total

Review 1.  Evaluation of current cancer immunotherapy: hemato-oncology.

Authors:  Christopher S Hourigan; Hyam I Levitsky
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.

Authors:  Nancy M Hardy; Vicki Fellowes; Jeremy J Rose; Jeanne Odom; Stefania Pittaluga; Seth M Steinberg; Bazetta Blacklock-Schuver; Daniele N Avila; Sarfraz Memon; Roger J Kurlander; Hahn M Khuu; Maryalice Stetler-Stevenson; Esther Mena; Andrew J Dwyer; Bruce L Levine; Carl H June; Ran Reshef; Robert H Vonderheide; Ronald E Gress; Daniel H Fowler; Frances T Hakim; Michael R Bishop
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

3.  Delivery of progenitors to the thymus limits T-lineage reconstitution after bone marrow transplantation.

Authors:  Daniel A Zlotoff; Shirley L Zhang; Maria Elena De Obaldia; Paul R Hess; Sarah P Todd; Theodore D Logan; Avinash Bhandoola
Journal:  Blood       Date:  2011-06-09       Impact factor: 22.113

4.  The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse.

Authors:  S J Coles; M N Gilmour; R Reid; S Knapper; A K Burnett; S Man; A Tonks; R L Darley
Journal:  Leukemia       Date:  2015-03-09       Impact factor: 11.528

Review 5.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

6.  Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation.

Authors:  Melinda A Biernacki; Yu-tzu Tai; Guang Lan Zhang; Anselmo Alonso; Wandi Zhang; Rao Prabhala; Li Zhang; Nikhil Munshi; Donna Neuberg; Robert J Soiffer; Jerome Ritz; Edwin P Alyea; Vladimir Brusic; Kenneth C Anderson; Catherine J Wu
Journal:  Blood       Date:  2012-01-20       Impact factor: 22.113

Review 7.  Precision in donor selection: Identifying ideal stem-cell donors through their T cells.

Authors:  Adam Widman; Ran Reshef
Journal:  Exp Hematol       Date:  2016-08-02       Impact factor: 3.084

8.  Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.

Authors:  Christian M Capitini; Nicole M Nasholm; Brynn B Duncan; Martin Guimond; Terry J Fry
Journal:  J Immunol       Date:  2012-12-28       Impact factor: 5.422

9.  Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.

Authors:  Simon F Lacey; Corinna La Rosa; Teodora Kaltcheva; Tumul Srivastava; Aprille Seidel; Wendi Zhou; Ravindra Rawal; Katharine Hagen; Aparna Krishnan; Jeff Longmate; Helen A Andersson; Lisa St John; Ravi Bhatia; Vinod Pullarkat; Stephen J Forman; Laurence J N Cooper; Jeffrey Molldrem; Don J Diamond
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

10.  Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Authors:  C Berlin; D J Kowalewski; H Schuster; N Mirza; S Walz; M Handel; B Schmid-Horch; H R Salih; L Kanz; H-G Rammensee; S Stevanović; J S Stickel
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.